Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide vs mesalazine vs placebo for induction of remission in lymphocytic colitis
2008-005994-36Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lymphocytic Colitis (LC) comparing Budenofalk 9 mg/day, Mesalazine 3 g/day and Placebo (3 arms). Primary endpoint: Clinical remission at week 8. Started Nov 2009; status: completed.
02
Drugs
budesonideSalcrozine
03
Conditions
Lymphocytic Colitis (LC)
Beyond the preview
Go deeper on 2008-005994-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005994-36.